Literature DB >> 10673291

Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.

L J van Doorn1, P M Schneeberger, N Nouhan, A P Plaisier, W G Quint, W A de Boer.   

Abstract

BACKGROUND: Virulence factors of Helicobacter pylori are associated with peptic ulcer disease and may be also associated with the efficacy of treatment. AIMS: To determine the relation between the vacA and the cagA status of H pylori, clinical disease, and treatment outcome. PATIENTS: 121 patients with H pylori infection and peptic ulcer disease or functional dyspepsia were treated by quadruple antibiotic therapy in two groups for one and two days, respectively.
METHODS: DNA was isolated from gastric antral biopsy specimens, taken before and after treatment, and the vacA and cagA status was determined by polymerase chain reaction and reverse hybridisation.
RESULTS: Peptic ulcer disease was significantly associated with the vacA s1 type, and cagA positivity, but not with the vacA m type. Treatment efficacy was significantly higher in patients with peptic ulcer disease, or infected with cagA+/vacA s1 strains.
CONCLUSIONS: The strong association between the cagA and vacA status and peptic ulcer disease was confirmed. Cure rates seem to be higher for patients with cagA+/vacA s1 H pylori strains, which is consistent with the higher cure rate observed among ulcer patients compared with functional dyspepsia patients. Therefore, treatment studies may require stratification for presence of ulcers as well as H pylori genotypes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10673291      PMCID: PMC1727836          DOI: 10.1136/gut.46.3.321

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  26 in total

1.  Rapid and simple method for purification of nucleic acids.

Authors:  R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

2.  Typing of Helicobacter pylori vacA gene and detection of cagA gene by PCR and reverse hybridization.

Authors:  L J van Doorn; C Figueiredo; R Rossau; G Jannes; M van Asbroek; J C Sousa; F Carneiro; W G Quint
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

3.  Geographic distribution of vacA allelic types of Helicobacter pylori.

Authors:  L J Van Doorn; C Figueiredo; F Mégraud; S Pena; P Midolo; D M Queiroz; F Carneiro; B Vanderborght; M D Pegado; R Sanna; W De Boer; P M Schneeberger; P Correa; E K Ng; J Atherton; M J Blaser; W G Quint
Journal:  Gastroenterology       Date:  1999-04       Impact factor: 22.682

4.  Helicobacter pylori and atrophic gastritis: importance of the cagA status.

Authors:  E J Kuipers; G I Pérez-Pérez; S G Meuwissen; M J Blaser
Journal:  J Natl Cancer Inst       Date:  1995-12-06       Impact factor: 13.506

5.  Weekend therapy for the treatment of Helicobacter pylori infection.

Authors:  A Tucci; L Poli; G F Paparo; P Bocus; T Togliani; C Mazzoni; G F Orcioni; R Agosti; W F Grigioni; S Sottili; G Caletti
Journal:  Am J Gastroenterol       Date:  1998-05       Impact factor: 10.864

6.  Expanding allelic diversity of Helicobacter pylori vacA.

Authors:  L J van Doorn; C Figueiredo; R Sanna; S Pena; P Midolo; E K Ng; J C Atherton; M J Blaser; W G Quint
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

Review 7.  Production of a cytotoxin by Helicobacter pylori.

Authors:  R D Leunk
Journal:  Rev Infect Dis       Date:  1991 Jul-Aug

Review 8.  The epidemiology of Helicobacter pylori infection.

Authors:  D N Taylor; M J Blaser
Journal:  Epidemiol Rev       Date:  1991       Impact factor: 6.222

9.  Two-day 'weekend' lansoprazole-quadruple therapy for Helicobacter pylori infection.

Authors:  W A de Boer; R J van Etten; A Coremans; P M Schneeberger
Journal:  Aliment Pharmacol Ther       Date:  1998-01       Impact factor: 8.171

10.  Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer.

Authors:  A Covacci; S Censini; M Bugnoli; R Petracca; D Burroni; G Macchia; A Massone; E Papini; Z Xiang; N Figura
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

View more
  42 in total

1.  Influence of smoking and CYP2C19 genotypes on H. pylori eradication success.

Authors:  T Suzuki; K Matsuo; A Sawaki; K Wakai; K Hirose; H Ito; T Saito; T Nakamura; K Yamao; N Hamajima; K Tajima
Journal:  Epidemiol Infect       Date:  2006-06-02       Impact factor: 2.451

2.  Evaluation of clarithromycin resistance and cagA and vacA genotyping of Helicobacter pylori strains from the west of Ireland using line probe assays.

Authors:  K A Ryan; L J van Doorn; A P Moran; M Glennon; T Smith; M Maher
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

3.  Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.

Authors:  Xiao-Min Liao; Gao-Hui Nong; Mei-Zu Chen; Xue-Ping Huang; Yun-Yan Cong; Yi-Ying Huang; Bai-He Wu; Jin-Qi Wei
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 4.  Second and third line treatment options for Helicobacter pylori eradication.

Authors:  Mingjun Song; Tiing Leong Ang
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

5.  The efficacy of laboratory diagnosis of Helicobacter pylori infections in gastric biopsy specimens is related to bacterial density and vacA, cagA, and iceA genotypes.

Authors:  L J van Doorn; Y Henskens; N Nouhan; A Verschuuren; R Vreede; P Herbink; G Ponjee; K van Krimpen; R Blankenburg; J Scherpenisse; W Quint
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

6.  Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy.

Authors:  Zaigham Abbas; Javed Yakoob; Shahab Abid; Wasim Jafri; Muhammad Islam; Zahid Azam; Imran Hilal
Journal:  Dig Dis Sci       Date:  2008-12-05       Impact factor: 3.199

Review 7.  Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-02-14       Impact factor: 4.291

Review 8.  How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?

Authors:  Enzo Ierardi; Floriana Giorgio; Giuseppe Losurdo; Alfredo Di Leo; Mariabeatrice Principi
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

9.  Helicobacter pylori therapy: Present and future.

Authors:  Vincenzo De Francesco; Enzo Ierardi; Cesare Hassan; Angelo Zullo
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-08-06

Review 10.  High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment.

Authors:  Mei Zhang
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.